EF Hutton initiated coverage of CytoSorbents with a Buy rating and $10 price target. The firm says the company’s filter cartridges, Cytosorb, and DrugSorb, “stand at the forefront of in vivo blood purification technologies.” The analyst is “enthusiastic” about the U.S. regulatory submission for DrugSorb to manage bleeding in coronary artery bypass graft patients. Following U.S. approval, EF anticipates a range of additional indications, including sepsis, kidney injury, and acute respiratory distress syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTSO:
- CTSO Upcoming Earnings Report: What to Expect?
- CytoSorbents files $150M mixed securities shelf
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
- CytoSorbents to present at inaugural AAPI World Health Congress
- CytoSorbents secures $20M credit facility